Reduced-dose RT with Cisplatin improves outcomes for HPV-associated oropharyngeal carcinoma

(NRG Oncology) A combination of reduced-dose radiotherapy using intensity-modulated radiotherapy (IMRT) combined with concurrent cisplatin met the threshold for disease control and quality of life compared to the standard of care for good-risk patients with HPV-associated oropharyngeal squamous cell carcinoma on the NRG Oncology clinical trial NRG-HN002.